Lundbeck Q3 2019 Financial Results

North America - strategic brands up 28% in 9M 2019 North America revenue (9M - DKKm) North America - strategic brands (Quarterly DKKm) * Declined 14% (19% in L.C.) to DKK 6,937 million in 9M 2019 I 9.000 2.000 Total sales impacted by generic introductions of clobazam in October 2018 -14% 8.000 7.000 * Excluding Onfi, sales up 13% in 6.000 1.500 Other products 9M 2019 5.000 A 1.000 Strategic brands# grew 28% to Abilify Maintena 4.000 DKK 4,912 million and Trintellix constituted 71% of revenue in 9M 2019 3.000 Northera 500 2.000 10 1.000 0 9M.18 9M.19 #) Abilify Maintena, Northera, Rexulti and Trintellix REXULTI +32% Q3.17 Q3.18 Q3.19 Lundbeck

View entire presentation